Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

In a strong validation of the company’s clinical trial, Imugene Ltd’s Phase 1b trial for its azer-cel off-the-shelf, allogeneic, CD19 CAR T therapy in relapsed/refractory diffuse large B-cell lymphoma ...

Gary Hogan wants you to know that while the Elks’ light may be temporarily dimmed due to the sale and demolition of their ...

However, the danger is that by organising such a workshop, the SAHRC has sought to secure ideological buy-in from the WCED, ...

Implantica reported a mixed financial performance for Q4 2024, with a 30% year-over-year decrease in quarterly revenue to €442,000, while full-year net sales rose by 38% to €1.9 million. The company's ...